Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
Status:
Unknown status
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy
and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel and Carboplatin versus
placebo and trastuzumab plus docetaxel and Carboplatin given as neoadjuvant treatment in HER2
positive early stage or locally advanced breast cancer.